TABLE 1

Clinical and biochemical characteristics in control subjects and in patients with type 2 diabetes before and after insulin treatment

VariablesControl groupDiabetes before treatmentDiabetes after treatment
n464040
Age (years)49.5 ± 550 ± 650.5 ± 6
Sex (M/F)24/2219/2119/21
BMI (kg/m2)24.4 ± 2.525.2 ± 2.224.8 ± 3.0
Systolic blood pressure (mmHg)122.3 ± 8.7126.8 ± 7.6121.4 ± 8.2
Diastolic blood pressure (mmHg)72.9 ± 6.274.3 ± 7.175.5 ± 6.9
Positive family history0 (0)3 (7.5)3 (7.5)
Smokers6 (13.0)5 (12.5)5 (12.5)
FBG (mmol/l)4.72 ± 0.469.87 ± 2.03*5.81 ± 0.76
2-h blood glucose (mmol/l)6.05 ± 0.6115.64 ± 2.96*7.13 ± 1.27*
A1C (%)5.23 ± 0.389.18 ± 1.25*6.33 ± 0.46
Total cholesterol (mmol/l)4.46 ± 0.335.80 ± 0.69*5.12 ± 0.41§
Triglycerides (mmol/l)1.35 ± 0.622.36 ± 0.84*1.77 ± 0.74§
LDL cholesterol (mmol/l)2.04 ± 0.363.53 ± 0.71*2.76 ± 0.52§
HDL cholesterol (mmol/l)1.28 ± 0.231.02 ± 0.211.11 ± 0.21
ApoA1 (g/l)1.13 ± 0.191.20 ± 0.221.17 ± 0.24
ApoB (g/l)0.98 ± 0.261.09 ± 0.191.17 ± 0.23
Lp(a) (mg/l)216 (56–512)241 (84–457)228 (62–606)
CRP (mg/l)1.13 ± 0.462.78 ± 0.77*1.78 ± 0.68
UAER (μg/min)8.3 (1–16)10.5 (3.3–16.8)9.7 (5–15.6)
Osteoprotegerin (ng/l)2.38 ± 0.253.44 ± 0.52*2.61 ± 0.55
  • Data are means ± SE, n (%), and median (range).

  • *

    * P < 0.01, compared with control group;

  • P < 0.01, compared with diabetes before treatment;

  • P < 0.05, compared with control group;

  • §

    § P < 0.05, compared with diabetes before treatment.